author-photo

A. Teule

45

Papers

127

Citations

Citation Trend

Filter By

Papers (29) Sort By

Journal Conference Others

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization.

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (2)
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.

2020 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (10)
1188TiP NICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
513P Prospective evaluation of the G8 screening tool for predicting survival in elderly patients with colon cancer

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Abstract P5-09-04: Impact of premenopausal RRSO on breast cancer risk in BRCA1/2 mutation carriers: Maximizing bias-reduction

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
1155PReal-world data of clinicopathologic characteristics of young oropharyngeal cancer patients

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (15)
P-310Efficacy of FOLFIRI as a second-line in extrapulmonary poorly-differentiated neuroendocrine carcinoma

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1387PDifferences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)